Historical record - last NADAC effective date: 5/22/2019
Product Information
LAMIVUDINE-ZIDOVUDINE TABLET is a generic product labeled by Exelan Pharmaceuticals Inc., priced at $1.2739 per EA under NDC 76282011560. Its NADAC has been published 187 times since Oct 28, 2015.
FDA first approved this application on Feb 3, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150; 300 mg/1; mg/1
Manufacturer
Exelan Pharmaceuticals Inc.NDC
76282011560
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
5/22/2019
Active Ingredients
LAMIVUDINE; ZIDOVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA203259FDA Approved
2/3/2014
TE Code
AB
On Market Since
4/29/2015
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has been published 187 times since Oct 28, 2015, and over the history we have for it it has declined 65.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2739 per EA |
|---|---|
| All-time high | $4.0868 (Feb 10, 2016) |
| All-time low | $0.8983 (Nov 21, 2018) |
| Median price | $1.6395 |
| Average price | $1.9239 |
| Largest weekly change | +46.1% (Dec 19, 2018) |
| Weeks tracked | 187 |
| Tracking since | Oct 28, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-65.7%
Last surveyed May 22, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 39% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Exelan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lamivudine and Zidovudine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMIVUDINE-ZIDOVUDINE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE-ZIDOVUDINE TABLET, manufactured by Exelan Pharmaceuticals Inc., is $1.2739 per EA (NDC 76282011560), effective May 22, 2019.
How has the price of LAMIVUDINE-ZIDOVUDINE TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has declined 65.7%. It has been tracked across 187 weekly CMS publications since Oct 28, 2015.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE-ZIDOVUDINE TABLET?
Since Oct 28, 2015, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has ranged from a low of $0.8983 (Nov 21, 2018) to a high of $4.0868 (Feb 10, 2016), with a median of $1.6395 per EA.
Are there cheaper alternatives to LAMIVUDINE-ZIDOVUDINE TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LAMIVUDINE-ZIDOVUDINE TABLET, is $0.7707 per EA — about 39% below LAMIVUDINE-ZIDOVUDINE TABLET.
Who manufactures LAMIVUDINE-ZIDOVUDINE TABLET?
LAMIVUDINE-ZIDOVUDINE TABLET (NDC 76282011560) is labeled by Exelan Pharmaceuticals Inc., and CMS classifies it as a generic product.